Anti Mullerian hormone as a diagnostic tool for polycystic ovary syndrome in women of reproductive age with morbid obesity.

Abstract

The aim of the study was to analyze the performance of the anti-mullerian hormone (AMH) level for the diagnosis of polycystic ovary syndrome in women with morbid obesity. A single-centre cross-sectional study was conducted in 50 women of reproductive age with a body mass index (BMI)≥40kg/m2. Each patient underwent a clinical examination, biological and hormonal assays, and an ovarian ultrasound between the third and the fifth day of the menstrual cycle. Polycystic ovary syndrome was diagnosed according to the Rotterdam's criteria. The mean age of participants was 34.2±7.5 years. Polycystic ovary syndrome was diagnosed in 20 women (40%). Age and anthropometric parameters did not differ between women with and without polycystic ovary syndrome. The mean AMH level was significantly higher in women with polycystic ovary syndrome (3.4±3.6 vs 1.3±1.2ng/ml, p=0.010). It was positively correlated with the Ferriman and Gallwey score (r=0.496, p=0.016), total testosterone level (r=0.524, p<10-3) andthe LH/FSH ratio (r=0.290, p=0.046). In women agedbetween 35 and 45 years, the optimum cut-off level for the diagnosis of polycystic ovary syndrome was 0.81ng/mL, providing a sensitivity and a specificity of 90and 71%, respectively with an area under the ROC curve of 0.857. AMH level was significantly higher in morbid obese women with polycystic ovary syndrome compared with those without polycystic ovary syndrome. Specific thresholds for this population must be assessed to improve the sensitivity and specificity of AMH for the diagnosis of polycystic ovary syndrome.